600420.SH
国药现代
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.45
−0.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.8B | 9.4B | 10.9B | 12.1B | 13.0B |
| Cost of Revenue | 6.1B | 6.3B | 6.6B | 7.4B | 8.0B |
| Gross Profit | 2.7B | 3.0B | 4.3B | 4.6B | 4.9B |
| Operating Expenses | |||||
| R&D Expense | 409.9M | 441.8M | 575.9M | 569.4M | 520.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 751.1M | 763.8M | 793.3M | 770.1M | 684.0M |
| Selling & Marketing Expense | 468.3M | 530.4M | 1.2B | 2.2B | 2.7B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.7B | 1.8B | 2.6B | 3.6B | 4.0B |
| Cost and Expenses | 7.9B | 8.1B | 9.2B | 11.0B | 12.0B |
| Operating Income (EBIT) | 1.1B | 1.3B | 1.8B | 1.1B | 966.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.1B | 1.3B | 1.7B | 1.1B | 984.1M |
| Income Tax Expense | 154.1M | 185.4M | 341.0M | 131.9M | 116.6M |
| Bottom Line | |||||
| Net Income | 718.6M | 941.6M | 1.1B | 691.9M | 627.8M |
| Earnings from Cont. Ops | 910.8M | 1.1B | 1.3B | 964.6M | 867.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 718.6M | 941.6M | 1.1B | 691.9M | 627.8M |
| Per Share | |||||
| Basic EPS | CN¥0.54 | CN¥0.70 | CN¥0.81 | CN¥0.54 | CN¥0.61 |
| Diluted EPS | CN¥0.54 | CN¥0.70 | CN¥0.81 | CN¥0.54 | CN¥0.54 |
| Revenue Per Share | CN¥6.58 | CN¥6.98 | CN¥8.16 | CN¥9.48 | CN¥12.62 |
| Shares | |||||
| Basic Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.3B | 1.0B |
| Diluted Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.3B | 1.0B |
| Profitability Metrics | |||||
| EBITDA | — | 2.0B | 2.5B | 1.9B | 1.8B |
| D&A | — | 723.5M | 778.3M | 825.2M | 836.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026